Titan Rises on Panel Backing Opioid Implant: San Francisco Mover
This article is for subscribers only.
Titan Pharmaceuticals Inc. rose the most in almost four years after U.S. regulatory advisers recommended approval for the company’s experimental implant to treat addiction to heroin and prescription painkillers.
Titan increased 36 percent to $1.67 at the close in New York, its biggest single-day gain since May 7, 2009. The Food and Drug Administration is scheduled to decide by April 30 whether to approve the treatment.